Soluble Urokinase Plasminogen Activator Receptor is Associated With Inflammation in the Vulnerable Human Atherosclerotic Plaque | Zendy

Andreas Edsfeldt | Zendy; Mihaela Nitulescu | Zendy; Helena Grufman | Zendy; Caitríona Grönberg | Zendy; Ana Persson | Zendy; Marie Nilsson | Zendy; Margaretha Persson | Zendy; Harry Björkbacka | Zendy; Isabel Gonçalves | Zendy

Open Access

Soluble Urokinase Plasminogen Activator Receptor is Associated With Inflammation in the Vulnerable Human Atherosclerotic Plaque

Author(s) -

Andreas Edsfeldt,

Mihaela Nitulescu,

Helena Grufman,

Caitríona Grönberg,

Ana Persson,

Marie Nilsson,

Margaretha Persson,

Harry Björkbacka,

Isabel Gonçalves

Publication year - 2012

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.112.664094

Subject(s) - supar , urokinase receptor , medicine , inflammation , proinflammatory cytokine , chemokine , monocyte , plasminogen activator , urokinase , pathology , immunology

Recently, plasma soluble urokinase plasminogen activator receptor (suPAR) has gained interest as a marker of cardiovascular risk. suPAR is released through the cleavage of urokinase plasminogen activator receptor (uPAR), which is found in monocytes, activated T-lymphocytes and endothelial cells, all involved in atherosclerosis. suPAR levels have been well studied in plasma, but no studies have focused on suPAR in human atherosclerotic plaques. The aim of this study was to determine whether suPAR measured in the plaque is associated with symptomatic plaques and plaque inflammation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research